Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 09, 2024 09:31 ET | Source: Spherix Global Insights

US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson’s Disease Treatments

Exton, Pennsylvania, May 09, 2024 (GLOBE NEWSWIRE) -- Even as the incidence of Parkinson’s disease (PD) continues to increase with 90,000 new diagnoses each year1 in the US, the treatment landscape...
February 05, 2021 09:00 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics to Present New Data on ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at WORLDSymposium™

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
May 27, 2020 16:30 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Announces Publication of Two New Papers Describing Its Blood-Brain Barrier Delivery Technology in Science Translational Medicine

Denali’s “Transport Vehicle” technology enables broad distribution and improved exposure levels of therapeutic proteins throughout the brainClinical proof of concept data with DNL310 (ETV:IDS), the...
February 27, 2020 16:30 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Reports Full Year 2019 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
August 06, 2019 16:30 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Reports Second Quarter 2019 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for...
August 05, 2019 09:00 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Announces That Its Partner Sanofi has Commenced Dosing of DNL758 in a Phase 1 Study

Sanofi has commenced dosing of DNL758 in a Phase 1 healthy volunteer study.DNL758 is an investigational small molecule RIPK1 inhibitor that does not cross the blood-brain barrier, and is intended for...
May 08, 2019 16:30 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Reports First Quarter 2019 Financial Results

SOUTH SAN FRANCISCO, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for...
March 12, 2019 09:00 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Reports Full Year 2018 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., March 12, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for...
December 10, 2018 09:00 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL201 for Parkinson’s Disease

Phase 1b study includes Parkinson’s disease patients with and without a genetic LRRK2 mutation SOUTH SAN FRANCISCO, Calif., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:...